Figure 2 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer

A coclinical trial framework reveals concordant patient–PDTX drug responses. A, Experimental framework (consisting of two trial designs) and associated analytical approach, with modeling metrics used to assess drug response. B and C, TV growth curves displaying linear mixed model fits of trial designs 1 (B) and 2 (C) over treatment duration. Treatment arm for each PDTX model corresponds to the clinical treatment of the matched patient. D and E, Analytical metrics derived from mathematical modeling (as in A). Change in growth rate (top) and estimated difference in the AUC (bottom) for trial design 1 (D) and growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 (E). F, Box plots displaying growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 between pCR and non-pCR models. Statistical significance is calculated using the Wilcoxon test.